CAS
EVGN icon

Coppell Advisory Solutions’s Evogene EVGN Stock Holding History

Coppell Advisory Solutions’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3
Closed -$18 – 1901
2024
Q2 		$18 Buy
+3
New +$21 ﹤0.01% 1776
2023
Q4 		$23 Sell
3
-3
-50% -$19 ﹤0.01% 1696
2023
Q3 		$42 Buy
6
+3
+100% +$26 ﹤0.01% 1171
2023
Q2 		$30 Buy
+3
New +$20 ﹤0.01% 1411
2023
Q1 		– Sell
-6
Closed -$42 – 475
2022
Q4 		$42 Buy
+6
New +$42 ﹤0.01% 1171

Other funds holding EVGN

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RIG
Renaissance Investment Group Lenox, Massachusetts $508M AUM 30.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Coppell Advisory Solutions's EVGN Position: Q3 2024 in Review

Coppell Advisory Solutions sold out of Evogene (EVGN) in Q3 2024, closing a stake of 3 shares — an estimated $18 sold.

Coppell Advisory Solutions first reported a position in EVGN in Q4 2022 and held it in 5 quarters. The position peaked at $42 in Q3 2023. 14 funds tracked by Wall St. Rank hold EVGN as of Q3 2024.

  • Coppell Advisory Solutions reported no remaining Evogene position as of Q3 2024 after selling out during the quarter.
  • Coppell Advisory Solutions sold 3 Evogene shares in Q3 2024, an estimated $18.
  • Coppell Advisory Solutions first reported a position in Evogene in Q4 2022 and held it in 5 quarters.
  • Coppell Advisory Solutions's Evogene position peaked at $42 in Q3 2023.
  • 14 funds tracked by Wall St. Rank held Evogene as of Q3 2024.

Based on Coppell Advisory Solutions's 13F filing for Q3 2024, filed 14 Nov 2024.